David Kirske

Chief Financial Officer

CTI Biopharma CorpX4 Pharmaceuticals, Inc

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 1 sale

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (17 ops.)

€1.8M

Latest filing published 05 Oct 2026 for X4 Pharmaceuticals, Inc, €30k.

Filing timeline

BuySale

David Kirske

Insider track record

Disclosed buys

Disclosed sells

Signal history

David Kirske: trading record in brief

David Kirske is a declared insider at 2 companies (finance chief); the most frequent names are CTI Biopharma Corp and X4 Pharmaceuticals, Inc. In total, 40 filings cover trades dated from 1 July 2020 to 1 October 2026.

Every open-market trade on record is a sale: 17 sales worth €1.8M. The rest of the record consists of 6 share grants and 16 option exercises. Since January 2026: no purchases and 1 sale on the market.

The record was last updated on 5 October 2026 with an open-market sale (€30k) in X4 Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.